Abstract

Neurocognitive difficulties are highly prevalent among people with schizophrenia and have been linked to increased inflammation, as well as dysfunction and disability. Poor neurocognitive functioning has also been documented in individuals at clinical high risk for psychosis (CHR) and a burgeoning literature point to alterations in inflammation markers in this population. However, there is limited information regarding the putative link between inflammation and neurocognition in CHR individuals, and the potential role of inflammation in the development of cognitive difficulties and psychosis. As previous reports indicate that early treatment in schizophrenia is associated with better outcomes, there is an urgent need to identify neurobiological mechanisms underlying cognitive deterioration and psychosis in CHR individuals to provide them with care prior to significant cognitive and functional declines. To address this gap in the literature, we review and summarize the relevant literatures on inflammation and neurocognitive dysfunction in schizophrenia and CHR individuals, point to remaining gaps, and suggest directions for future research.

MeSH

Psychiatry, Psychotic Disorders, Risk, Schizophrenia, Nervous System Diseases, Neurology

Cited by

• Reduced glymphatic clearance in early psychosis. Mol Psychiatry, 2025
• Postnatal Antioxidant and Anti-inflammatory Treatments Prevent Early Ketamine-Induced Cortical Dysfunctions in Adult Mice. Front Neurosci, 2020
• Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia. J Psychiatr Brain Sci, 2020
• Association between Peripheral Inflammatory Cytokines and Cognitive Function in Patients with First-Episode Schizophrenia. J Pers Med, 2022
• Sex and regional differences in gene expression across the striatum in psychosis. Transl Psychiatry, 2025
• Is psychosis a syndemic manifestation of historical and contemporary adversity? Findings from UK Biobank. Br J Psychiatry, 2022
• The Effects of Peripheral Inflammation on the Brain-A Neuroimaging Perspective. Harv Rev Psychiatry, 2022
• Immune-Inflammatory Biomarkers Predict Cognition and Social Functioning in Patients With Type 2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A 1-Year Follow-Up Study. Front Neurol, 2022
• Emerging Roles of Non-coding RNAs on Symptom Type and Cognitive Functions in Schizophrenia and Schizoaffective Disorder. Clin Psychopharmacol Neurosci, 2025
• Association between white blood cell counts and the efficacy on cognitive function after rTMS intervention in schizophrenia. Schizophrenia (Heidelb), 2025
• Supplementation with Lentil () Hull Soluble Dietary Fiber Ameliorates Sodium Dextran Sulfate-Induced Colitis and Behavioral Deficits via the Gut-Brain Axis. Foods, 2025
• Affective predictors of social support in individuals with schizophrenia. Schizophr Res, 2025
• The Neutrophil-Lymphocyte Ratio Is Positively Correlated with Aggression in Schizophrenia. Biomed Res Int, 2022
• Relationships Between Immune-Inflammatory Features and Social Cognitive Impairments in Patients With Schizophrenia Spectrum Disorders: A Systematic Review. Brain Behav, 2025
• Placental inflammatory cytokines mRNA expression and preschool children's cognitive performance: a birth cohort study in China. BMC Med, 2023
• Determining the Role of Sex and APOE4 status on Psychosis in Alzheimer's Disease. J Geriatr Psychiatry Neurol, 2025
• Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention. Front Cell Neurosci, 2022
• Basic Symptoms Are Associated With Age in Patients With a Clinical High-Risk State for Psychosis: Results From the PRONIA Study. Front Psychiatry, 2020